CLINICAL TRIALS

Prostate Cancer Clinical Trials in Maryland

10+ recruiting Prostate Cancer trials in Maryland, simplified into plain English.

Informational only. Not medical advice. Always consult a qualified healthcare professional.
Data sourced from ClinicalTrials.gov (NLM/NIH).

RECRUITINGPhase 3

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to thei

NCT05939414 · Baltimore
RECRUITINGPhase 1

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Pelunt

NCT05652686 · Baltimore
ACTIVE NOT RECRUITINGPhase 2

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this s

NCT04126070 · Baltimore
ACTIVE NOT RECRUITINGNA

Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer

A prospective, multi-center, single-arm study, planned in 150 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultraso

NCT02766543 · Baltimore
RECRUITINGPhase 1

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

NCT06785636 · Baltimore
RECRUITINGPhase 1

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

Background: Metastatic castration sensitive and castration resistant prostate cancer (mCSPC and mCRPC) are prostate cancers that have spread to other parts of the body. Use of the drug docetaxel with androgen deprivatio

NCT04633252 · Bethesda
ACTIVE NOT RECRUITING

Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies

Background: Prostate cancer is one of the most common cancers in men. For some men, their cancer is monitored. Others have surgery to remove the prostate. Focal therapy is another treatment option. It treats the areas o

NCT04541030 · Bethesda
ACTIVE NOT RECRUITINGPhase 1

Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer

This study will be undertaken to evaluate the feasibility of replacing systemic Androgen Deprivation Therapy (ADT) with targeted local delivery of an anti-androgen agent alone in patients in whom ADT + radiation therapy

NCT04943536 · Bethesda
RECRUITING

Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

Background: Prostate cancer is the most common noncutaneous cancer among men in the U.S. Researchers want to study blood, tissue, and fluid samples of people with prostate cancer. This will help them understand any chan

NCT02594202 · Bethesda
RECRUITINGPhase 1

Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe

Prostate cancer (PCa) is the most diagnosed type of cancer and the second leading cause of cancer related deaths among US men, and its incidence has increased steadily in the last decade. Efforts to address the rise in P

NCT07271017 · Baltimore

RECOMMENDED RESOURCES FOR PROSTATE CANCER

🛡️

GoHealth

Medicare Specialist

Compare Medicare Advantage and Supplement plans with a licensed advisor. Many patients with chronic conditions qualify for $0-premium plans with extra benefits.

Check Your Coverage →
🧬

Color Health

CLIA Certified

Hereditary cancer genetic testing from $99. Understand your inherited risk for breast, ovarian, colon, and other cancers — with genetic counseling included.

Get Tested →

Clinicals AI may earn a referral fee. At no cost to you.

COMMON QUESTIONS

Are there Prostate Cancer clinical trials in Maryland?

Yes. Clinicals AI lists 10+ recruiting Prostate Cancer trials in Maryland sourced from ClinicalTrials.gov. Browse them above or search across all states.

How do I qualify for a Prostate Cancer trial in Maryland?

Eligibility varies by study. Most trials require a confirmed Prostate Cancer diagnosis, fall within a specific age range, and may have restrictions based on prior treatments. Review each listing's criteria and submit a contact request for more details.

Are Prostate Cancer clinical trials free to join?

Most trials cover the investigational treatment and all study-related visits. Some also offer compensation for travel and time. Always confirm the cost structure with the trial coordinator before enrolling.